BACKGROUND/AIM: Insulin-like growth factors (IGFs) and IGF binding proteins (IGFBPs) play a role in the normal development of breast tissue, and possibly in breast cancer aetiology. IGFBP2, one of six members of the IGFBP superfamily, acts as regulator of the IGFs and has pleiotropic effects in normal and neoplastic tissues. Because IGFs have mitogenic effects on mammary epithelia, this study investigated IGFBP2 expression in mammary tissues of different benign and malignant entities. METHODS: Immunohistochemistry was used to study correlations between the presence and intensity of IGFBP2 staining and tumour type and grade, in addition to steroid hormone receptor status, in 120 breast specimens. Expression was measured by quantitative colour video image analysis and semiquantitative evaluation, and the measurements correlated well (r = 0.92; p<0.05). RESULTS: Both methods found no significant expression of IGFBP2 in normal glandular cells and hyperplasia (group I). Atypical hyperplasia showed a slightly increased cytoplasmic expression of IGFBP2, and carcinoma in situ showed a distinctive, membrane associated and cytoplasmic expression (group II). Infiltrating carcinomas strongly expressed cytoplasmic IGFBP2 (group III). There were significant differences between group I and II, and between group II and III. There were no significant differences between invasive lobular and invasive ductal carcinoma, or between grades I, II, and III within these entities. There was no significant correlation between IGFBP2 immunostaining and oestrogen or progesterone receptor positivity within the malignant group. CONCLUSIONS: IGFBP2 mitogenic signals of autocrine/paracrine regulatory mechanisms may be responsible for the growth of breast carcinomas and IGFBP2 may be an independent indicator of malignancy.
BACKGROUND/AIM: Insulin-like growth factors (IGFs) and IGF binding proteins (IGFBPs) play a role in the normal development of breast tissue, and possibly in breast cancer aetiology. IGFBP2, one of six members of the IGFBP superfamily, acts as regulator of the IGFs and has pleiotropic effects in normal and neoplastic tissues. Because IGFs have mitogenic effects on mammary epithelia, this study investigated IGFBP2 expression in mammary tissues of different benign and malignant entities. METHODS: Immunohistochemistry was used to study correlations between the presence and intensity of IGFBP2 staining and tumour type and grade, in addition to steroid hormone receptor status, in 120 breast specimens. Expression was measured by quantitative colour video image analysis and semiquantitative evaluation, and the measurements correlated well (r = 0.92; p<0.05). RESULTS: Both methods found no significant expression of IGFBP2 in normal glandular cells and hyperplasia (group I). Atypical hyperplasia showed a slightly increased cytoplasmic expression of IGFBP2, and carcinoma in situ showed a distinctive, membrane associated and cytoplasmic expression (group II). Infiltrating carcinomas strongly expressed cytoplasmic IGFBP2 (group III). There were significant differences between group I and II, and between group II and III. There were no significant differences between invasive lobular and invasive ductal carcinoma, or between grades I, II, and III within these entities. There was no significant correlation between IGFBP2 immunostaining and oestrogen or progesterone receptor positivity within the malignant group. CONCLUSIONS:IGFBP2 mitogenic signals of autocrine/paracrine regulatory mechanisms may be responsible for the growth of breast carcinomas and IGFBP2 may be an independent indicator of malignancy.
Authors: D Yee; R E Favoni; R Lupu; K J Cullen; G S Lebovic; K K Huff; P D Lee; Y L Lee; D R Powell; R B Dickson Journal: Biochem Biophys Res Commun Date: 1989-01-16 Impact factor: 3.575
Authors: Chad P Garner; Yuan C Ding; Esther M John; Sue A Ingles; Olufunmilayo I Olopade; Dezheng Huo; Clement Adebamowo; Temidayo Ogundiran; Susan L Neuhausen Journal: Hum Genet Date: 2008-01-22 Impact factor: 4.132
Authors: Mary L Disis; Ekram Gad; Daniel R Herendeen; Vy Phan- Lai; Kyong Hwa Park; Denise L Cecil; Megan M O'Meara; Piper M Treuting; Ronald A Lubet Journal: Cancer Prev Res (Phila) Date: 2013-10-23
Authors: Kristen S Purrington; Susan Slager; Diana Eccles; Drakoulis Yannoukakos; Peter A Fasching; Penelope Miron; Jane Carpenter; Jenny Chang-Claude; Nicholas G Martin; Grant W Montgomery; Vessela Kristensen; Hoda Anton-Culver; Paul Goodfellow; William J Tapper; Sajjad Rafiq; Susan M Gerty; Lorraine Durcan; Irene Konstantopoulou; Florentia Fostira; Athanassios Vratimos; Paraskevi Apostolou; Irene Konstanta; Vassiliki Kotoula; Sotiris Lakis; Meletios A Dimopoulos; Dimosthenis Skarlos; Dimitrios Pectasides; George Fountzilas; Matthias W Beckmann; Alexander Hein; Matthias Ruebner; Arif B Ekici; Arndt Hartmann; Ruediger Schulz-Wendtland; Stefan P Renner; Wolfgang Janni; Brigitte Rack; Christoph Scholz; Julia Neugebauer; Ulrich Andergassen; Michael P Lux; Lothar Haeberle; Christine Clarke; Nirmala Pathmanathan; Anja Rudolph; Dieter Flesch-Janys; Stefan Nickels; Janet E Olson; James N Ingle; Curtis Olswold; Seth Slettedahl; Jeanette E Eckel-Passow; S Keith Anderson; Daniel W Visscher; Victoria L Cafourek; Hugues Sicotte; Naresh Prodduturi; Elisabete Weiderpass; Leslie Bernstein; Argyrios Ziogas; Jennifer Ivanovich; Graham G Giles; Laura Baglietto; Melissa Southey; Veli-Matti Kosma; Hans-Peter Fischer; Malcom W R Reed; Simon S Cross; Sandra Deming-Halverson; Martha Shrubsole; Qiuyin Cai; Xiao-Ou Shu; Mary Daly; Joellen Weaver; Eric Ross; Jennifer Klemp; Priyanka Sharma; Diana Torres; Thomas Rüdiger; Heidrun Wölfing; Hans-Ulrich Ulmer; Asta Försti; Thaer Khoury; Shicha Kumar; Robert Pilarski; Charles L Shapiro; Dario Greco; Päivi Heikkilä; Kristiina Aittomäki; Carl Blomqvist; Astrid Irwanto; Jianjun Liu; Vernon Shane Pankratz; Xianshu Wang; Gianluca Severi; Arto Mannermaa; Douglas Easton; Per Hall; Hiltrud Brauch; Angela Cox; Wei Zheng; Andrew K Godwin; Ute Hamann; Christine Ambrosone; Amanda Ewart Toland; Heli Nevanlinna; Celine M Vachon; Fergus J Couch Journal: Carcinogenesis Date: 2013-12-09 Impact factor: 4.944